Original articleGenomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse
Introduction
Acute myeloid leukemia (AML) is a rapidly proliferating neoplasm of immature hematopoietic cells. Diagnostic karyotype is well established as the best independent prognostic factor for AML for complete remission as well as for disease-free and overall survival. Normal karyotype (NK) AML is the most common AML cytogenetic group, comprising 40–49% of adult and 20–25% of pediatric AML diagnoses. NK AML is associated with an intermediate prognosis, defined as a 5-year survival rate of 24–40% [1], [2]. Despite the importance of diagnostic karyotype [3], however, 25–51% of NK AML patients will have AML associated with aberrant karyotype (AK) at relapse [4], [5], [6], [7]. It is unknown how these previously cytogenetically normal AML cells “acquire” additional genetic abnormalities [5]. One possibility is that AK AML cells were present but undetected at time of NK AML diagnosis as a result of low cell frequency and the relative insensitivity of conventional cytogenetic analyses. Recent analyses have shown that most relapsed pediatric acute lymphocytic leukemia (ALL) disease arises from minor tumor subpopulations present but undetected at time of diagnosis [8]. Alternatively, AK AML cells could have arisen from acquired genetic changes to preexisting NK AML cells. Finally, AK AML cells may represent secondary de novo leukemia cells.
To elucidate the etiology of AK AML after NK AML, we identified 17 patients with diagnostic NK AML and relapsed AK AML (designated NK-AK AML) treated at our institute. We compared cytogenetic and immunophenotypic profiles, and NPM1/FLT3 gene mutation status from patient samples at diagnosis and relapse. In addition, we performed high-resolution array-based comparative genomic hybridization (aCGH) on all diagnostic NK AML samples specifically looking for chromosomal aberrations that might have been present but undetected by conventional karyotyping [9], [10], [11].
Section snippets
Patient samples
Under an IRB-approved protocol, we reviewed data on 301 consecutive NK AML patients diagnosed at our institute between 1991 and 2009. Clinical outcomes were defined per Cheson et al. [12]. Relapse was defined as the finding of >5% marrow blasts not attributable to another cause or to extramedullary disease. Event-free survival was defined as time between relapse and death from any cause. Sixty patients had karyotype information at both diagnosis and time of disease progression and/or relapse.
Clinical characteristics
Characteristics of the 17 NK-AK AML patients evaluated here are summarized in Table 1. All patients received induction therapy with cytarabine- and anthracycline-based induction AML regimens before relapse or recurrence. Overall time and time to AK AML development were 470 ± 213 days and 294 ± 198 days, respectively. Event-free survival (or survival after AK AML diagnosis) was only 96 ± 64 days.
Cytogenetics
Abnormal karyotypes at relapse in these 17 patients were complex (defined as three or more
Discussion
We examined immunophenotype profiles and NPM1/FLT3 gene mutation status in 17 paired NK-AK AML samples at diagnosis and relapse. In contrast with prior studies demonstrating a high frequency of immunophenotypic [21] and gene mutation changes (specifically NRAS, FLT3, and TP53) between AML diagnosis and relapse [22], we found that most paired NK-AK AML samples (>83%) did not demonstrate significant antigen or NPM1/FLT3 mutational changes over time. We did not, however, specifically evaluate NRAS
Acknowledgments
This research was supported in part by the Szefel Leukemia Research Fund (RPCI) and a National Cancer Institute Cancer Center support grant (CA016156).
Thanks to Daniel P. Gaile, Lori Shepherd, Song Liu, Jeff Miecznikowski (SUNY-UB and RPCI Biostatistics), Paul Wallace (RPCI Flow Cytometry), AnneMarie W. Block (RPCI Cytogenetics), Maurice Barcos (RPCI Hematopathology), Marc S. Halfon (SUNY-UB COE), and the RPCI Leukemia Service for excellent patient care.
References (43)
- et al.
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties
Blood
(1998) - et al.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Blood
(2002) - et al.
Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse
Cancer Genet Cytogenet
(1989) - et al.
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
J Mol Diagn
(2003) - et al.
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia
J Mol Diagn
(2009) - et al.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Blood
(2001) - et al.
Patterns of clonal evolution in transformed chronic myelogenous leukemia
Cancer Genet Cytogenet
(1995) - et al.
Detection of DNA copy number alterations in cancer by array comparative genomic hybridization
Genet Med
(2007) - et al.
Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia
Cancer Genet Cytogenet
(2004) - et al.
Challenges in array comparative genomic hybridization for the analysis of cancer samples
Genet Med
(2007)